Analyze the Commercial Potential for Sanctura XR, A Recently-Approved Next-Generation Overactive Bladder (OAB) Agent.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c42806) has announced the addition of the new report from Datamonitor "Financial Markets Research: Indevus Pharmaceuticals Sanctura XR - Last-to-market Entrant Unlikely to Make an Impact in Crowded OAB Market" to their offering.

The lack of differentiation between overactive bladder agents has led manufacturers to turn to large-scale marketing efforts in an attempt to gain market share. Given the relatively small marketing capabilities of IDEV and Esprit, they may have difficulty penetrating high-prescribing urology and primary care practices compared to its larger rivals, thus slowing Sanctura XRs near-term potential.

Scope of this title:

This title analyzes the commercial potential for IDEVs Sanctura XR, a recently-approved next-generation OAB agent. For this report we interviewed twenty-four urologists regarding trends in the treatment of OAB and the potential role of next-generation Sanctura XR

Highlights of this title include:

Based on the data from the Phase II trial, we anticipate that once-daily Sanctura XR will demonstrate a safety and efficacy profile comparable to the original twice-daily Sanctura formulation and support its FDA approval in mid/late 2007.

Interviewed physicians indicated that all currently marketed OAB products have comparable safety and efficacy profiles and, as the last once-daily OAB option to come to market, if approved, Sanctura XR would not dramatically impact their OAB prescribing habits given the crowded OAB market.

Reasons to order your copy:

To understand the commercial potential for Sanctura XR in the treatment of OAB through in-depth analysis based on interviews with leading experts.

This report anticipates likely changes in the future market dynamics for overactive bladder agents given the entry of a new market player.

Overactive Bladder: Overview

-- Pharmacotherapy dominated by anticholinergic agents

-- Wide variety of long-acting once-daily OAB agents available

-- Improved dosing profile of Sanctura XR aims to boost IDEVs OAB franchise

Factors Affecting The Potential For Sanctura Xr

-- Little differentiation versus available options likely to diminish Sanctura XRs potential

-- Can David compete with multiple Goliaths in crowded OAB market?

Our Sanctura Xr Forecast

-- Based on small Phase II and proven technology, FDA approval appears likely

-- Even if approved, Sanctura XR not likely to make a splash in crowded OAB market

-- Agents with novel mechanisms of action may change future treatment of OAB

List of Tables Include:

Table 1: Near-term IDEV Milestones

Table 2: Currently marketed branded OAB agents

Table 3: Forecast US Sanctura / Sanctura XR franchise revenues 2006-2010

Table 4: Pipeline OAB agents

Table 5: OAB Model 2006-2010

For more information visit http://www.researchandmarkets.com/reports/c42806

Source: Datamonitor